The interaction between these two important antileukemic drugs can cause inter-individual variability in dexamethasone and asparaginase pharmacokinetics, which may influence the efficacy and toxicity of ALL treatment. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.